Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Apr;20(4):387-405.
doi: 10.6004/jnccn.2022.0020.

Management of Immunotherapy-Related Toxicities, Version 1.2022, NCCN Clinical Practice Guidelines in Oncology

John A Thompson  1 , Bryan J Schneider  2 , Julie Brahmer  3 , Amaka Achufusi  4 , Philippe Armand  5 , Meghan K Berkenstock  3 , Shailender Bhatia  1 , Lihua E Budde  6 , Saurin Chokshi  7 , Marianne Davies  8 , Amro Elshoury  9 , Yaron Gesthalter  10 , Aparna Hegde  11 , Michael Jain  12 , Benjamin H Kaffenberger  13 , Melissa G Lechner  14 , Tianhong Li  15 , Alissa Marr  16 , Suzanne McGettigan  17 , Jordan McPherson  18 , Theresa Medina  19 , Nisha A Mohindra  20 , Anthony J Olszanski  21 , Olalekan Oluwole  22 , Sandip P Patel  23 , Pradnya Patil  24 , Sunil Reddy  25 , Mabel Ryder  26 , Bianca Santomasso  27 , Scott Shofer  28 , Jeffrey A Sosman  20 , Yinghong Wang  29 , Vlad G Zaha  30 , Megan Lyons  31 , Mary Dwyer  31 , Lisa Hang  31
Affiliations
Review

Management of Immunotherapy-Related Toxicities, Version 1.2022, NCCN Clinical Practice Guidelines in Oncology

John A Thompson et al. J Natl Compr Canc Netw. 2022 Apr.

Abstract

The aim of the NCCN Guidelines for Management of Immunotherapy-Related Toxicities is to provide guidance on the management of immune-related adverse events resulting from cancer immunotherapy. The NCCN Management of Immunotherapy-Related Toxicities Panel is an interdisciplinary group of representatives from NCCN Member Institutions, consisting of medical and hematologic oncologists with expertise across a wide range of disease sites, and experts from the areas of dermatology, gastroenterology, endocrinology, neurooncology, nephrology, cardio-oncology, ophthalmology, pulmonary medicine, and oncology nursing. The content featured in this issue is an excerpt of the recommendations for managing toxicities related to CAR T-cell therapies and a review of existing evidence. For the full version of the NCCN Guidelines, including recommendations for managing toxicities related to immune checkpoint inhibitors, visit NCCN.org.

PubMed Disclaimer

Substances